Work

In Brief: Keytruda Qlex – A Subcutaneous Formulation of Pembrolizumab

Year: 2025

Type: article

Source: The medical letter on drugs and therapeutics/The medical letter

DOI: 10.58347/tml.2025.1741f

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4415958700

FWCI:

Cites:

Cited by:

Related to: